Melatonin Inhibits EMT in Bladder Cancer by Targeting Autophagy.

Content Provider	Europe PMC
Author	Hsiao, Sheng-Yen Tang, Chih-Hsin Chen, Po-Chun Lin, Tien-Huang Chao, Chia-Chia
Editor	Grant, George
Copyright Year	2022
Abstract	Melatonin, a naturally biosynthesized molecule secreted by the pineal gland, exhibits antitumor activities against several different types of cancer. The mechanisms of action of melatonin against tumor progression involve cellular apoptosis, antimetastatic activity, antioxidant and mutagenic effects, antiangiogenic activity, and the restoration of cancer immune surveillance. Melatonin has anticancer activity when administered alone or in combination with standard chemotherapeutic agents, with measurable improvements seen in the clinical endpoints of tumor regression and patient survival. However, scant clinical evidence supports the use of melatonin in bladder cancer treatment. Our study has found that melatonin treatment suppresses the bladder cancer cell migratory ability by inhibiting the epithelial-mesenchymal transition (EMT) process, which appears to be linked to melatonin-induced decreases in bladder cancer cell autophagy. Finally, an evaluation of in vivo melatonin-induced antitumor effects in an orthotopic animal model of bladder cancer indicated that melatonin treatment slightly prolonged the survival of tumor-bearing mice. Our study offers novel insights into the use of melatonin in bladder cancer treatment.
Journal	Molecules
Volume Number	27
DOI	10.3390/molecules27248649
PubMed Central reference number	PMC9784694
Issue Number	24
PubMed reference number	36557782
e-ISSN	14203049
Language	English
Publisher	Molecular Diversity Preservation International (MDPI)
Publisher Date	2022-12-07
Access Restriction	Open
Subject Keyword	melatonin EMT autophagy bladder cancer
Content Type	Text
Resource Type	Article
Subject	Physical and Theoretical Chemistry Medicine Chemistry Drug Discovery Pharmaceutical Science Analytical Chemistry Molecular Medicine Organic Chemistry